AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31880308 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 15846
Study 31880308 — intervention group
Group type: COMPARATOR
Intervention: Other bDMARDs
Number of subjects: 15846
Study 31880806 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implants (CIs)
Number of subjects: 10
Study 31880806 — intervention group
Group type: COMPARATOR
Intervention: Normal hearing control group
Number of subjects: 10
Study 31880950 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 44
Study 31881608 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound surveillance (Doppler ultrasound)
Number of subjects: 1000
Study 31881608 — intervention group
Group type: COMPARATOR
Intervention: Sequential compression devices
Number of subjects: 1000
Study 31881616 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzymatic digestion combined with mechanical distortion
Number of subjects: 20
Study 31881616 — intervention group
Group type: COMPARATOR
Intervention: Enzymatic digestion
Number of subjects: 20
Study 31881616 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical distortion
Number of subjects: 20
Study 31881616 — intervention group
Group type: EXPERIMENTAL
Intervention: Excised adipose tissue
Number of subjects: 20
Study 31881616 — intervention group
Group type: COMPARATOR
Intervention: Aspirated adipose tissue
Number of subjects: 20
Study 31881853 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib (daily oral at full dose for 18 cycles of 28 days)
Number of subjects: 150
Study 31881853 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib
Number of subjects: 150
Study 31882281 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab (3 cycles)
Number of subjects: 82
Study 31882281 — intervention group
Group type: EXPERIMENTAL
Intervention: mpMRI assessment
Number of subjects: 82
Study 31882377 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR T cells with CD28 co-stimulatory domain
Number of subjects: 5
Study 31883202 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic cancer risk assessment (GCRA)
Number of subjects: 20
Study 31883202 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions to reduce disparities in GCRA uptake
Number of subjects: 20
Study 31883202 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted interventions
Number of subjects: 20
Study 31883396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib combined with bortezomib and dexamethasone
Number of subjects: 76
Study 31883529 — intervention group
Group type: EXPERIMENTAL
Intervention: Microglia from mucolipidosis type IV
Number of subjects: 2
Study 31883529 — intervention group
Group type: COMPARATOR
Intervention: Microglia from Fabry disease mice
Number of subjects: 2
Study 31883679 — intervention group
Group type: EXPERIMENTAL
Intervention: High platelet FcγRIIa expression (>11,000/platelet) in patients identified as high risk by the GRACE score
Number of subjects: 197
Study 31883679 — intervention group
Group type: EXPERIMENTAL
Intervention: High platelet FcγRIIa expression (>11,000/platelet) in patients identified as high risk by the DAPT score
Number of subjects: 197
Study 31883679 — intervention group
Group type: EXPERIMENTAL
Intervention: High platelet FcγRIIa expression
Number of subjects: 197
Study 31883966 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety manipulation (threat-of-shock)
Number of subjects: 0
Study 31883966 — intervention group
Group type: COMPARATOR
Intervention: Fear (not explicitly manipulated in this study)
Number of subjects: 0
Study 31884564 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost SR 6 µg
Number of subjects: 75
Study 31884564 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost SR 10 µg
Number of subjects: 75
Study 31884564 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost SR 15 µg
Number of subjects: 75
Study 31884564 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost SR 20 µg
Number of subjects: 75
Study 31884564 — intervention group
Group type: COMPARATOR
Intervention: Topical bimatoprost 0.03% (Control)
Number of subjects: 75
Study 31884564 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study eyes (all doses combined)
Number of subjects: 75
Study 31884564 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (AEs)
Number of subjects: 75
Study 31884676 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK's IIV4 (one dose)
Number of subjects: 1060
Study 31884676 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK's IIV4 (second dose)
Number of subjects: 1060
Study 31884676 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK's IIV4
Number of subjects: 1060
Study 31885047 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian stimulation for IVF/ICSI in patients with isthmocele
Number of subjects: 103
Study 31885047 — intervention group
Group type: COMPARATOR
Intervention: Ovarian stimulation for IVF/ICSI in patients without isthmocele
Number of subjects: 103
Study 31885349 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (N-TKI group)
Number of subjects: 31
Study 31885349 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (N-chemo group)
Number of subjects: 31
Study 31885697 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation
Number of subjects: 0
Study 31885697 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31885750 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg mepolizumab (subcutaneous)
Number of subjects: 9
Study 31885756 — intervention group
Group type: EXPERIMENTAL
Intervention: sEMG recording of temporalis and masseters
Number of subjects: 50
Study 31885756 — intervention group
Group type: EXPERIMENTAL
Intervention: sEMG recording of temporalis
Number of subjects: 50
Study 31885756 — intervention group
Group type: EXPERIMENTAL
Intervention: sEMG combined with clinical evaluation
Number of subjects: 50
Study 31885895 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic deep lateral wall bony decompression with partial rim sparing (DLW-PRS) using SONOPET® ultrasonic aspirator.
Number of subjects: 35
Study 31886028 — intervention group
Group type: EXPERIMENTAL
Intervention: M-MIST and PRF
Number of subjects: 36
Study 31886028 — intervention group
Group type: COMPARATOR
Intervention: M-MIST alone
Number of subjects: 36
Study 31886253 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium + ischemia
Number of subjects: 35
Study 31886253 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin + ischemia
Number of subjects: 35
Study 31886253 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium + Melatonin + ischemia
Number of subjects: 35
Study 31886253 — intervention group
Group type: COMPARATOR
Intervention: Ischemia group
Number of subjects: 35
Study 31886253 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 31886877 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine lavage procedure
Number of subjects: 81
Study 31886877 — intervention group
Group type: COMPARATOR
Intervention: IVF control cycle
Number of subjects: 81
Study 31887145 — intervention group
Group type: EXPERIMENTAL
Intervention: PNNS-GS2 (Programme National Nutrition Santé Guidelines Score 2)
Number of subjects: 54089
Study 31887274 — intervention group
Group type: EXPERIMENTAL
Intervention: En bloc EMR (e-EMR)
Number of subjects: 570
Study 31887274 — intervention group
Group type: COMPARATOR
Intervention: Piecemeal EMR (p-EMR)
Number of subjects: 570
Study 31887431 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg qd)
Number of subjects: 22
Study 31887443 — intervention group
Group type: EXPERIMENTAL
Intervention: NAFLD
Number of subjects: 898
Study 31887443 — intervention group
Group type: EXPERIMENTAL
Intervention: FIB-4 scores greater than 2.67
Number of subjects: 898
Study 31887443 — intervention group
Group type: EXPERIMENTAL
Intervention: NFS scores greater than 0.676
Number of subjects: 898
Study 31888507 — intervention group
Group type: EXPERIMENTAL
Intervention: RF-SLAM (random forest for SLAM data analysis)
Number of subjects: 0
Study 31888507 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of preceding heart failure hospitalizations
Number of subjects: 0
Study 31888588 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory waiting room (lighting column, rhythmic music)
Number of subjects: 0
Study 31888588 — intervention group
Group type: COMPARATOR
Intervention: Traditional waiting room
Number of subjects: 0
Study 31888588 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer waiting time
Number of subjects: 0
Study 31888588 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit purpose (dental examination or treatment with conscious sedation)
Number of subjects: 0
Study 31888643 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic P. falciparum monoinfection
Number of subjects: 16959
Study 31888643 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic P. vivax monoinfection
Number of subjects: 16959
Study 31888643 — intervention group
Group type: COMPARATOR
Intervention: No Plasmodium detected initially
Number of subjects: 16959
Study 31888672 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched therapy
Number of subjects: 3487
Study 31888672 — intervention group
Group type: COMPARATOR
Intervention: Unmatched therapy
Number of subjects: 3487
Study 31888703 — intervention group
Group type: EXPERIMENTAL
Intervention: rs10865710 polymorphism
Number of subjects: 1131
Study 31888721 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pulsatile perfusion
Number of subjects: 32
Study 31888721 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocapnia
Number of subjects: 32
Study 31888721 — intervention group
Group type: EXPERIMENTAL
Intervention: MCAv/PaCO2 relationship
Number of subjects: 32
Study 31888931 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmed IMD cases (15-24 years 11 months at time of disease)
Number of subjects: 128
Study 31888931 — intervention group
Group type: COMPARATOR
Intervention: Control participants (17-34 years 11 months)
Number of subjects: 128
Study 31888941 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based decision aid and planning tool for family-building after cancer (accessed post-baseline survey)
Number of subjects: 100
Study 31889230 — intervention group
Group type: EXPERIMENTAL
Intervention: Dotinurad 1 mg (single oral administration)
Number of subjects: 12
Study 31889307 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT), 12-16 sessions
Number of subjects: 28
Study 31889307 — intervention group
Group type: EXPERIMENTAL
Intervention: Cingulo-opercular structural connections
Number of subjects: 28
Study 31890041 — intervention group
Group type: EXPERIMENTAL
Intervention: EVO 2.5 mg
Number of subjects: 146
Study 31890041 — intervention group
Group type: EXPERIMENTAL
Intervention: EVO 5 mg
Number of subjects: 146
Study 31890041 — intervention group
Group type: EXPERIMENTAL
Intervention: EVO 10 mg
Number of subjects: 146
Study 31890041 — intervention group
Group type: COMPARATOR
Intervention: SITA 100 mg
Number of subjects: 146
Study 31890043 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-months exercise program (a combination of aerobic and strength training for a minimum of 150 min per week)
Number of subjects: 137
Study 31890043 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 137
Study 31890160 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime/avibactam (CAZ-AVI) plus metronidazole
Number of subjects: 0
Study 31890160 — intervention group
Group type: COMPARATOR
Intervention: Ceftolozane/tazobactam plus metronidazole
Number of subjects: 0
Study 31890160 — intervention group
Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 0
Study 31890195 — intervention group
Group type: EXPERIMENTAL
Intervention: Diathermy (Hot group)
Number of subjects: 29
Study 31890195 — intervention group
Group type: COMPARATOR
Intervention: Knife excision (Cold group)
Number of subjects: 29
Study 31890261 — intervention group
Group type: EXPERIMENTAL
Intervention: CCAs (Collaborative Care Approaches) used by adolescents to inform their S.M.A.R.T. goals over a 3-week period
Number of subjects: 50
Study 31890261 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group) where adolescents set S.M.A.R.T. goals without CCAs
Number of subjects: 50
Study 31890266 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week physical activity intervention (4 weekly aerobic and strength training sessions)
Number of subjects: 16
Study 31890266 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 16
Study 31890266 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 16
Study 31890631 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate passwords for intervention access
Number of subjects: 0
Study 31890631 — intervention group
Group type: COMPARATOR
Intervention: Grade-8 reading level passwords for intervention access
Number of subjects: 0
Study 31890850 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio programme plus community engagement (LDGs, street theatre, local leader messaging)
Number of subjects: 1440
Study 31890850 — intervention group
Group type: COMPARATOR
Intervention: Radio programming alone
Number of subjects: 1440
Study 31890902 — intervention group
Group type: EXPERIMENTAL
Intervention: V7 TB vaccine (10 µg of hydrolyzed heat-killed mycobacteria)
Number of subjects: 0
Study 31890902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31890996 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy (LLT) including statin and/or ezetimibe
Number of subjects: 3033
Study 31890996 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy (LLT)
Number of subjects: 3033
Study 31891134 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard condoms
Number of subjects: 504
Study 31891134 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin condoms
Number of subjects: 504
Study 31891134 — intervention group
Group type: EXPERIMENTAL
Intervention: Condoms fitted to each user's penile dimensions
Number of subjects: 504
Study 31891135 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX followed by Stereotactic Body Radiotherapy (SBRT) (5 fractions/8 Gy)
Number of subjects: 50
Study 31891145 — intervention group
Group type: EXPERIMENTAL
Intervention: GAIN+EUC
Number of subjects: 112
Study 31891145 — intervention group
Group type: COMPARATOR
Intervention: EUC
Number of subjects: 112
Study 31891235 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy
Number of subjects: 216
Study 31891235 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy
Number of subjects: 216
Study 31891235 — intervention group
Group type: EXPERIMENTAL
Intervention: INCREMENT-CPE mortality score ≥8
Number of subjects: 216
Study 31891447 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients with diabetes
Number of subjects: 1443
Study 31891447 — intervention group
Group type: COMPARATOR
Intervention: Hypertensive patients without diabetes
Number of subjects: 1443
Study 31891447 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1443
Study 31891695 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA (patient-controlled epidural analgesia)
Number of subjects: 344
Study 31891695 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 344
Study 31891695 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterolateral thoracotomy
Number of subjects: 344
Study 31891695 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterolateral thoracotomy
Number of subjects: 344
Study 31891695 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA
Number of subjects: 344
Study 31891878 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole combined with CDK inhibition
Number of subjects: 30
Study 31891967 — intervention group
Group type: EXPERIMENTAL
Intervention: Embrace WetBond sealant
Number of subjects: 90
Study 31891967 — intervention group
Group type: COMPARATOR
Intervention: ART sealant
Number of subjects: 90
Study 31892445 — intervention group
Group type: EXPERIMENTAL
Intervention: One-piece patient-specific reconstruction plate for double-barrel fibula flap reconstruction
Number of subjects: 0
Study 31892445 — intervention group
Group type: COMPARATOR
Intervention: Standard reconstruction methods (implied control)
Number of subjects: 0
Study 31892518 — intervention group
Group type: EXPERIMENTAL
Intervention: TST
Number of subjects: 3593
Study 31892518 — intervention group
Group type: EXPERIMENTAL
Intervention: QFT-GIT
Number of subjects: 3593
Study 31892518 — intervention group
Group type: EXPERIMENTAL
Intervention: T-SPOT
Number of subjects: 3593
Study 31892518 — intervention group
Group type: COMPARATOR
Intervention: TST-positive, IGRA-negative results
Number of subjects: 3593
Study 31892644 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised approach to patient education about cardiovascular risk factors, physical activity (PA), and a healthy diet integrated into existing rehabilitation settings.
Number of subjects: 0
Study 31892644 — intervention group
Group type: COMPARATOR
Intervention: Historical control from a prospective national cohort study on body mass index (BMI).
Number of subjects: 0
Study 31892671 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral Robotic Surgery (TORS) with tailored radiotherapy
Number of subjects: 25
Study 31893018 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Number of subjects: 0
Study 31893211 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid therapy
Number of subjects: 80
Study 31893211 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of inclusion bodies
Number of subjects: 80
Study 31893211 — intervention group
Group type: EXPERIMENTAL
Intervention: High-grade positivity on IHC
Number of subjects: 80
Study 31893211 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic CMV viral load
Number of subjects: 80
Study 31893211 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood CMV viral load
Number of subjects: 80
Study 31893211 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 31893211 — intervention group
Group type: EXPERIMENTAL
Intervention: Mayo score and blood CMV expression
Number of subjects: 80
Study 31893514 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV5-hFVIII-SQ gene therapy
Number of subjects: 15
Study 31894377 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) treatment in treatment-naïve patients
Number of subjects: 147
Study 31894377 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) treatment in previously treated patients
Number of subjects: 147
Study 31894377 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) treatment
Number of subjects: 147
Study 31894702 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational survey and tailored advertising campaign
Number of subjects: 7059
Study 31894702 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpaid media events
Number of subjects: 7059
Study 31894702 — intervention group
Group type: EXPERIMENTAL
Intervention: Print media characteristics
Number of subjects: 7059
Study 31894702 — intervention group
Group type: EXPERIMENTAL
Intervention: Media events
Number of subjects: 7059
Study 31894704 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic oral vinorelbine in combination with immune-checkpoint inhibitors
Number of subjects: 71
Study 31895148 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning analysis using gradient-boosted multivariate regressions (GBM)
Number of subjects: 285
Study 31895148 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal predictors with GBM
Number of subjects: 285
Study 31895148 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health problems and hematocrit levels in longitudinal models
Number of subjects: 285
Study 31895148 — intervention group
Group type: COMPARATOR
Intervention: Machine learning vs logistic regression
Number of subjects: 285
Study 31895484 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training on NICE classification
Number of subjects: 30
Study 31895484 — intervention group
Group type: COMPARATOR
Intervention: No training
Number of subjects: 30
Study 31895484 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training
Number of subjects: 30
Study 31895484 — intervention group
Group type: EXPERIMENTAL
Intervention: High-confidence level
Number of subjects: 30
Study 31895611 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 420 at 400 μg/d (maximum tolerated dose)
Number of subjects: 42
Study 31895611 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 420 at 0.2-800 μg/d
Number of subjects: 42
Study 31895611 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 420 at 800 μg/d
Number of subjects: 42
Study 31895611 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 420 at 400 μg/d
Number of subjects: 42
Study 31895695 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning exercise (10 hours after DLMO)
Number of subjects: 52
Study 31895695 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening exercise (20 hours after DLMO)
Number of subjects: 52
Study 31895695 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning exercise for later chronotypes
Number of subjects: 52
Study 31895695 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening exercise for later chronotypes
Number of subjects: 52
Study 31895695 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning exercise for earlier chronotypes
Number of subjects: 52
Study 31895695 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening exercise for earlier chronotypes
Number of subjects: 52
Study 31895696 — intervention group
Group type: EXPERIMENTAL
Intervention: U-mtDNA levels in smokers without COPD
Number of subjects: 483
Study 31895696 — intervention group
Group type: EXPERIMENTAL
Intervention: U-mtDNA levels in males
Number of subjects: 483
Study 31895696 — intervention group
Group type: EXPERIMENTAL
Intervention: U-mtDNA levels in females
Number of subjects: 483
Study 31895696 — intervention group
Group type: COMPARATOR
Intervention: UACR levels
Number of subjects: 483
Study 31895987 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography Airway Count
Number of subjects: 0
Study 31895987 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31896448 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma concentration of UCHL1
Number of subjects: 427
Study 31896448 — intervention group
Group type: EXPERIMENTAL
Intervention: BDNF plasma concentration
Number of subjects: 427